Search Results for: PLEKHF2

176 interactions involving PLEKHF2 - pleckstrin homology and FYVE domain containing 2 found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
L3MBTL3 L3MBTL histone methyl-lysine binding protein 3
LDOC1 LDOC1 regulator of NFKB signaling
MAGI2 membrane associated guanylate kinase, WW and PDZ domain containing 2
  • Nephrin family interactions
MAP2K1 mitogen-activated protein kinase kinase 1
  • MAPK3 (ERK1) activation
  • Frs2-mediated activation
  • Signal transduction by L1
  • Uptake and function of anthrax toxins
  • RAF activation
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by MAP2K mutants
  • Signaling by RAF1 mutants
  • K-252a
  • 5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
  • Cobimetinib
  • Bosutinib
  • (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide
  • 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide
  • PD-0325901
  • N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine
  • 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE
  • Trametinib
  • Selumetinib
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
MAX MYC associated factor X
  • Transcription of E2F targets under negative control by DREAM complex
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • Transcriptional Regulation by E2F6
MBIP MAP3K12 binding inhibitory protein 1
  • HATs acetylate histones
MBP myelin basic protein
  • EGR2 and SOX10-mediated initiation of Schwann cell myelination
MEAF6 MYST/Esa1 associated factor 6
  • HATs acetylate histones
  • HATs acetylate histones
  • Regulation of TP53 Activity through Acetylation
MFAP1 microfibril associated protein 1
  • Molecules associated with elastic fibres
MIDN midnolin
MPP4 membrane palmitoylated protein 4
MRI1 methylthioribose-1-phosphate isomerase 1
  • Methionine salvage pathway
NDUFA5 NADH:ubiquinone oxidoreductase subunit A5
  • Respiratory electron transport
  • Complex I biogenesis
  • NADH
NFIA nuclear factor I A
  • RNA Polymerase III Transcription Termination
  • RNA Polymerase III Abortive And Retractive Initiation
NONO non-POU domain containing octamer binding
NPM2 nucleophosmin/nucleoplasmin 2
NSD2 nuclear receptor binding SET domain protein 2
  • PKMTs methylate histone lysines
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Nonhomologous End-Joining (NHEJ)
  • Processing of DNA double-strand break ends
  • G2/M DNA damage checkpoint
  • Multiple myeloma
NUDT2 nudix hydrolase 2
  • Detoxification of Reactive Oxygen Species
NUTM1 NUT midline carcinoma family member 1
P2RX7 purinergic receptor P2X 7
  • Elevation of cytosolic Ca2+ levels
  • Platelet homeostasis
  • The NLRP3 inflammasome
  • The NLRP3 inflammasome
  • Purinergic signaling in leishmaniasis infection
  • Promethazine

Page 5 out of 9 pages